SCHEMBL1961762

SCHEMBL1961762

CN(C(=O)c1ccc(Cl)cc1Cl)c1cc(C#CC(C)(C)C)sc1C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NR1I2 O75469 2/20 0.40
▸ CYP2E1 P05181 1/20 0.40
▸ TSHR P16473 1/20 0.39
▸ CASP1 P29466 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ CYP3A4 P08684 1/20 0.37
▸ FSCN1 Q16658 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ SRD5A2 P31213 1/20 0.34
▸ GABRA1 P14867 3/20 0.33
▸ GABRG2 P18507 3/20 0.33
▸ GABRB3 P28472 3/20 0.33
▸ GABRB2 P47870 2/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ ACLY P53396 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1963307 0.88 CYP2E1 (0.39) NR1I2CYP2E1TSHRCASP1SMN1; SMN2
SCHEMBL1963830 0.87 CYP3A4 (0.50) NR1I2CYP2E1TSHRCASP1SMN1; SMN2
SCHEMBL1958417 0.87 CYP2E1 (0.38) NR1I2CYP2E1TSHRCASP1SMN1; SMN2
SCHEMBL14973222 0.86 CYP2E1 (0.43) NR1I2CYP2E1TSHRCASP1SMN1; SMN2
SCHEMBL1963185 0.86 NR1I2 (0.45) NR1I2CYP2E1TSHRCASP1SMN1; SMN2
SCHEMBL324463 0.85 CYP2E1 (0.45) NR1I2CYP2E1TSHRCASP1SMN1; SMN2
SCHEMBL1958434 0.85 NR1I2 (0.47) NR1I2CYP2E1TSHRCASP1SMN1; SMN2
SCHEMBL1961765 0.84 NR1I2 (0.46) NR1I2CYP2E1TSHRCASP1SMN1; SMN2
SCHEMBL1958761 0.84 CYP2E1 (0.42) NR1I2CYP2E1TSHRCASP1SMN1; SMN2
SCHEMBL670264 0.83 NR1I2 (0.44) NR1I2CYP2E1TSHRCASP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130136719-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-05-30 — — US claimed
EP-2504329-A1 5-ALKYNYL-THIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS Vertex Pharmaceuticals Incorporated (US) 2012-10-03 — — EP claimed
WO-2011068715-A1 5-ALKYNYL-THIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-06-09 — — WO claimed
US-20130136719-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-05-30 — — US disclosed
US-20130136719-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-05-30 — — US disclosed
US-20130136719-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-05-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130136719-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS HAVCR2, GTF3C3, ZC3HAV1 NR1I2 312/4885CYP2E1 75/4885TSHR 1935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback